198 related articles for article (PubMed ID: 19138543)
1. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
3. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it.
Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY
Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640
[TBL] [Abstract][Full Text] [Related]
4. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors.
Kansal N; Silakari O; Ravikumar M
Eur J Med Chem; 2010 Jan; 45(1):393-404. PubMed ID: 19892442
[TBL] [Abstract][Full Text] [Related]
5. A three-dimensional pharmacophore model for IMPDH inhibitors.
Yang N; Wang J; Li J; Wang QH; Wang Y; Cheng MS
Chem Biol Drug Des; 2011 Jul; 78(1):175-82. PubMed ID: 21507206
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potential ZAP-70 kinase inhibitors: pharmacophore design, database screening and docking studies.
Sanam R; Vadivelan S; Tajne S; Narasu L; Rambabu G; Jagarlapudi SA
Eur J Med Chem; 2009 Dec; 44(12):4793-800. PubMed ID: 19674816
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
Lu A; Zhang J; Yin X; Luo X; Jiang H
Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
[TBL] [Abstract][Full Text] [Related]
11. Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.
Krovat EM; Langer T
J Med Chem; 2003 Feb; 46(5):716-26. PubMed ID: 12593652
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors.
Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW
Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors.
Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y
J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
[TBL] [Abstract][Full Text] [Related]
16. 3D-pharmacophore models for selective A2A and A2B adenosine receptor antagonists.
Wei J; Wang S; Gao S; Dai X; Gao Q
J Chem Inf Model; 2007; 47(2):613-25. PubMed ID: 17330954
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore identification of Raf-1 kinase inhibitors.
Zhu T; Jiao Y; Chen YD; Wang X; Li HF; Zhang LY; Lu T
Bioorg Med Chem Lett; 2008 Apr; 18(7):2346-50. PubMed ID: 18346893
[TBL] [Abstract][Full Text] [Related]
18. Investigation of potential glycogen synthase kinase 3 inhibitors using pharmacophore mapping and virtual screening.
Dessalew N; Bharatam PV
Chem Biol Drug Des; 2006 Sep; 68(3):154-65. PubMed ID: 17062013
[TBL] [Abstract][Full Text] [Related]
19. Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
Zhang J; Yu K; Zhu W; Jiang H
Bioorg Med Chem Lett; 2006 Jun; 16(11):3009-14. PubMed ID: 16530411
[TBL] [Abstract][Full Text] [Related]
20. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
